This is what Alex Denner should be discussing with BP presuming they have such a product! My own speculation is that the right dosage and delivery system would provide patient benefit for most (if not all types) of cancer. Too bad past management never seemed to figure this out. Maybe Alex Denner is keeping this confidential so as not to alert the competition. BP may understand some of these EPA benefits but do not see a viable way to capitalize on it. What we hope Denner is doing is showing BP that there may be a path for them to move EPA into a class of drugs where it should have been (if not for stupid management and moronic Judge Du) and to have a version of EPA that could be patent protected by BP. This is what I hope is or will be going on! Of course, in my world "hope" seems to be a four letter word.
Market Data 
Markets 
AI
